Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cancer Vaccines01:30

Cancer Vaccines

510
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
510

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing of the first dressing change after CVC insertion in pediatric critically ill patients: a randomized controlled, non-inferiority trial.

Scientific reports·2026
Same author

Genome-Wide Identification, Evolutionary Analysis and Seasonal Expression Patterns of the Sox Gene Family in the Daurian Ground Squirrel (<i>Spermophilus dauricus</i>).

Veterinary sciences·2026
Same author

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients.

Blood cancer journal·2026
Same author

Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.

Blood·2026
Same author

Factors associated with first-attempt success of peripheral arterial catheterization in a pediatric intensive care unit: a prospective observational study.

Frontiers in pediatrics·2026
Same author

Ginsenoside-Rh2 inhibits U251 glioma cell migration and invasion via the Gab2/Akt2 pathway.

Frontiers in oncology·2026

Related Experiment Video

Updated: Sep 12, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

797

CD7 CAR-T therapy: current developments, improvements, and dilemmas.

Linjuan Wang1,2, Shaowei Qiu1,2

  • 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Blood Science (Baltimore, Md.)
|August 7, 2025
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell therapy targeting CD7 shows promise for relapsed/refractory T-cell leukemias. Allogeneic CAR-T cells offer advantages but face challenges like GVHD, with gene editing and novel cell sources providing potential solutions.

Keywords:
AMLCAR-TCD7GVHDclinical applicationfratricider/r T-ALL/LBL

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Related Experiment Videos

Last Updated: Sep 12, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

797
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy has revolutionized B-cell malignancies treatment.
  • Its application in T-cell malignancies, particularly T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) and acute myeloid leukemia (AML), remains a significant challenge.
  • CD7 has emerged as a key target antigen for T-cell malignancies.

Purpose of the Study:

  • To review the different categories of CD7 CAR-T products.
  • To discuss their clinical applications and challenges.
  • To explore potential solutions and future directions for CD7 CAR-T therapy.

Main Methods:

  • Review of existing literature on CD7 CAR-T therapy.
  • Analysis of autologous versus allogeneic CAR-T cell products.
  • Examination of challenges such as graft-versus-host disease (GVHD), host-versus-graft reaction (HVGR), and fratricide.
  • Exploration of gene-editing techniques (CRISPR/Cas9, base editing) and novel cell sources (NKT cells, iPSCs).

Main Results:

  • Allogeneic CD7 CAR-T cells demonstrate advantages in manufacturing cost, quality consistency, affordability, and availability compared to autologous CAR-T cells.
  • Significant challenges including GVHD, HVGR, and fratricide impede the clinical use of allogeneic CD7 CAR-T cells.
  • Innovative gene-editing technologies and alternative cell sources are being investigated to overcome these hurdles.

Conclusions:

  • CD7 CAR-T therapy holds significant potential for treating relapsed/refractory T-cell malignancies.
  • Allogeneic approaches offer practical benefits but require mitigation of immune-related toxicities.
  • Advancements in gene editing and cell sourcing are crucial for the successful clinical translation of CD7 CAR-T therapies.